Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Chris Papagiannis"'
Impurity Qualification Toxicology Study for a 2′-O-Methoxyethyl-Modified Antisense Inhibitor in Mice
Autor:
Andrew McPherson, Scott P. Henry, David Serota, Daniel C. Capaldi, Christine Hoffmaster, Nhuy Luu, Farah Mahdi, Tae-Won Kim, Andrew A. Rodriguez, Chris Papagiannis
Publikováno v:
Nucleic Acid Therapeutics. 30:14-21
Safety assessment of drug impurities is a routine part of the drug development process. For oligonucleotide-based drugs, impurities can arise from impurities in starting materials, as by-products of the manufacturing process or from degradation, and
Autor:
Laura S. Zwick, Jill Hsiao, Chris Papagiannis, Jeffery A. Engelhardt, Noah Post, Scott P. Henry, Tae-Won Kim, John Matson, Sebastien A. Burel, Christine Hoffmaster
Publikováno v:
Toxicologic Pathology. 47:82-92
The 6-month Tg.rasH2 mouse carcinogenicity model provides an acceptable alternative to the 2-year carcinogenicity study in CD-1 mice. However, key questions related to the use of this model for testing antisense oligonucleotides (ASOs) include the si
Autor:
Lijiang Shen, David Serota, Shin-Young Park, Yunlip Kim, Tae-Won Kim, Scott P. Henry, Thomas A. Zanardi, Chris Papagiannis
Publikováno v:
Nucleic Acid Therapeutics. 28:233-241
Advances in antisense oligonucleotide (ASO) chemistry and screening have enabled the design and selection of molecules that are optimized for a particular therapeutic application in terms of both potency and tolerability. The most-well studied of the